Trial Profile

Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 19 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tusamitamab ravtansine (Primary) ; Carboplatin; Cisplatin; Pembrolizumab
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms CARMEN-LC05
Sponsors Sanofi; Sanofi-Aventis Recherche & Developpement

10 Jan 2025 Status changed from active, no longer recruiting to discontinued.
06 Feb 2024 Planned End Date changed from 25 Apr 2025 to 30 Dec 2024.
06 Feb 2024 Planned primary completion date changed from 4 Sep 2024 to 10 Apr 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com